Table 4.
Comparison of HT and sequential therapy in the eradication of Helicobacter pylori
| First author, year | Region | Centers (n) | Duration | Cases (n) | Cure rate of ITT (%) | Cure rate of PP (%) | Compliance (%) | Overall rate of adverse effects (%) | Discontinued medication due to adverse effects (%) |
|---|---|---|---|---|---|---|---|---|---|
| Hsu, 2011[6,16] | Taiwan, China | 3 | 14d HT | 117 | 97.4 | 99.1* | 94.9 | 14.5 | 4.3 |
| 14d ST | 123 | 91.9 | 93.9 | 95.9 | 21.1 | 3.3 | |||
| Sardarian, 2013[17] | Iran | 1 | 14d HT | 210 | 89.5* | 92.9* | 96.7 | 28.1 | 1.4 |
| 10d ST | 210 | 76.7 | 79.9 | 98.6 | 24.8 | 0.5 | |||
| Zullo, 2013[18] | Italy | 3 | 14d HT | 90 | 80.0 | 85.7 | 93.3 | 24.4 | 6.7 |
| 10d ST | 90 | 91.1 | 92.1 | 98.9 | 18.9 | 1.1 | |||
| Oh, 2014[11] | Korea | 1 | 14d HT | 90 | 81.1 | 85.9 | 97.7 | 33.7 | 3.5 |
| 14d ST | 94 | 79.8 | 82.0 | 95.7 | 39.8 | 3.2 | |||
| De Francesco, 2014[19] | Italy | 1 | 14d HT | 110 | 82.7 | 95.8 | NR | 22.7 | 6.4 |
| 10d ST | 110 | 90.0 | 94.3 | NR | 19.1 | 2.7 | |||
| Chen, 2015[8] | Taiwan, China | 1 | 14d HT | 88 | 92.0* | 96.4* | 97.7 | 59.1 | 2.3 |
| 10d ST | 87 | 78.2 | 81.9 | 97.6 | 69.0 | 2.3 | |||
| Pooled-data analysis | HT | 705 | 87.8 (619/705) | 93.0 (608/654) | 96.1 (566/589) | 29.1 (204/701) | 3.7 (26/701) | ||
| ST | 714 | 83.8 (598/714) | 86.6 (589/680) | 97.5 (586/601) | 29.9 (213/713) | 2.0 (14/713) |
*P<0.05: HT versus ST. CT: Concomitant therapy; HT: Hybrid therapy; ITT: Intention-to-treat; NR: Not reported; PP: Per-protocol; ST: Sequential therapy; d: Days.